These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 27744089)
1. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. Gandhi PU; Gaggin HK; Redfield MM; Chen HH; Stevens SR; Anstrom KJ; Semigran MJ; Liu P; Januzzi JL JACC Heart Fail; 2016 Nov; 4(11):860-869. PubMed ID: 27744089 [TBL] [Abstract][Full Text] [Related]
2. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Gandhi PU; Gaggin HK; Sheftel AD; Belcher AM; Weiner RB; Baggish AL; Motiwala SR; Liu PP; Januzzi JL Am J Cardiol; 2014 Nov; 114(10):1543-9. PubMed ID: 25248814 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288 [TBL] [Abstract][Full Text] [Related]
4. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399 [TBL] [Abstract][Full Text] [Related]
5. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860 [TBL] [Abstract][Full Text] [Related]
6. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Jacobshagen C; Belardinelli L; Hasenfuss G; Maier LS Clin Cardiol; 2011 Jul; 34(7):426-32. PubMed ID: 21538388 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843 [TBL] [Abstract][Full Text] [Related]
8. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E; JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662 [TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction. Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226 [TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme. Ferreira JP; Packer M; Sattar N; Butler J; González Maldonado S; Panova-Noeva M; Sumin M; Masson S; Pocock SJ; Anker SD; Zannad F; Januzzi JL Eur J Heart Fail; 2024 Apr; 26(4):806-816. PubMed ID: 38587259 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521 [TBL] [Abstract][Full Text] [Related]
12. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B; JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441 [TBL] [Abstract][Full Text] [Related]
13. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD; J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245 [TBL] [Abstract][Full Text] [Related]
14. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792 [TBL] [Abstract][Full Text] [Related]
15. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898 [TBL] [Abstract][Full Text] [Related]
16. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction. Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148 [TBL] [Abstract][Full Text] [Related]
17. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. Wang H; Anstrom K; Ilkayeva O; Muehlbauer MJ; Bain JR; McNulty S; Newgard CB; Kraus WE; Hernandez A; Felker GM; Redfield M; Shah SH JAMA Cardiol; 2017 Aug; 2(8):896-901. PubMed ID: 28492915 [TBL] [Abstract][Full Text] [Related]
18. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Reddy YNV; Lewis GD; Shah SJ; Obokata M; Abou-Ezzedine OF; Fudim M; Sun JL; Chakraborty H; McNulty S; LeWinter MM; Mann DL; Stevenson LW; Redfield MM; Borlaug BA Mayo Clin Proc; 2019 Jul; 94(7):1199-1209. PubMed ID: 31272568 [TBL] [Abstract][Full Text] [Related]
20. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]